Compare JetBlue Airways Corporation (JBLU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs TransMedics Group Inc — how do they compare? JetBlue Airways Corporation trades at $5.86 (market cap $2.19B), while TransMedics Group Inc trades at $87.47 (market cap $3.10B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| JBLU | TMDX | |
|---|---|---|
Market Cap | $2.19B | $3.10B |
Sector | Industrials | Technology |
52-Week High | $6.46 | $150.42 |
52-Week Low | $4.03 | $61.99 |
Enterprise Value | $9.56B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.87, up 4.08% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings beat with a loss of $0.66 per share versus expectations of $0.69, though it has missed estimates in two of the last three quarters. Recent news includes Citigroup's downgrade to Sell on August 11, 2026, citing geopolitical risks, while the company introduced new fare structures and lounge accolades.
Outlook remains challenging with persistent net losses and negative margins, but cost management and strategic initiatives like the 2028 profit target offer potential upside. Key risks include high fuel costs, debt levels, and competitive pressure. Analyst consensus is cautious with a $5.18 price target and 62% Hold ratings, suggesting limited near-term growth amid operational headwinds.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
